New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:00 EDTINCYIncyte ruxolitinib data 'a home run, ' says Oppenheimer
After Incyte reported results from a Phase III study of its ruxolitinib in polycythemia vera, Oppenheimer expects the drug to be approved and generate significant commercial sales. The firm keeps a $75 price target and Outperform rating on the stock.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
07:36 EDTINCYIncyte earns $25M milestone payment from Novartis for Jakavi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use